TiumBio to Participate in BioUSA... Seeking Partnerships Including Marigolics

Tiium Bio, a company specializing in the research and development of treatments for rare and intractable diseases, announced on the 30th that it will participate in the 2024 BIO International Convention (BIO USA) held from June 3 to 6 (local time) in San Diego, California, USA. BIO USA is the largest global convention in the pharmaceutical and biotechnology industry, where industry professionals gather to discuss partnering and other opportunities.

Tiium Bio logo [Photo by Tiium Bio]

At Tiium Bio, Vice President Kim Jeong-hoon, who oversees the Development Headquarters, and Director Yoon Seok-won of the Business Development Office will participate to seek global partnerships for new drug pipelines including Marigolicx (TU2670) for the treatment of endometriosis and uterine fibroids, TU7710 for hemophilia, and TU2218, an immuno-oncology agent.

Vice President Kim Jeong-hoon stated, “Marigolicx demonstrated excellent efficacy and safety in the Phase 2 clinical trial for endometriosis, and we are also looking forward to the clinical results of TU7710 and TU2218, which are scheduled to be announced in the second half of the year. We will actively promote the clinical results and market potential of our new drug candidates at BIO USA to showcase our global business development achievements.”

This content was produced with the assistance of AI translation services.